待处理
入排:排除
图源:待检查
入排置信度 0.99
The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
Alexey V Danilov, Ian W Flinn, Matthew S Davids, Beth Gregory, Ohad Bentur, David Sidransky, Jennifer R Brown
Haematologica 109(10) 3379-3382
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板